Latest news
Maverex celebrates its women-owned business status
Posted on June 9, 2020Maverex celebrates its women-owned business status At the end of May 2020, Maverex was formally recognised by WEConnect International, a not-for-profit organisation working to connect women-owned and controlled businesses globally. Maverex was awarded with a certification for Women’s Business Enterprise; acknowledging Maverex not only as a women-owned company, but as also wanting to do …
Read more
New publication from Maverex on COPD
Posted on December 9, 2019New publication from Maverex – Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review – in Respiratory Research We are delighted to announce that our latest publication, a systematic review of the safety and efficacy of single-inhaler triple therapies for chronic obstructive pulmonary disorder (COPD), is now available at Respiratory …
Read more
Maverex launch innovative digital tools at ISPOR 2019
Posted on November 2, 2019Maverex launch innovative digital tools at ISPOR 2019 – Interactive Model Builder and Payer Value Platform With the theme of ISPOR Europe 2019 being ‘Digital Transformation of Healthcare’, it’s the perfect time to launch our exciting new digital tools and we can’t wait to share them with you. Following on from the success …
Read more
Maverex posters at ISPOR Copenhagen 2019
Posted on October 4, 2019Maverex posters at ISPOR Copenhagen 2019 It’s that time of the year again, and the Maverex team is delighted to be attending ISPOR Europe in Copenhagen! As well as enjoying the beautiful city, we are keen to be there for presentations and discussions on the latest in determining value in healthcare and to catch …
Read more
Latest Maverex publication – Transparency in Decision Modelling
Posted on July 25, 2019Latest Maverex publication – Transparency in Decision Modelling Read our latest manuscript recently published in PharmacoEconomics – “Transparency in Decision Modelling: What, Why, Who and How?” We are pleased to share details of our most recent publication, which Nina, Antony and Sue have been involved in developing, discussing the opportunities and potential risks …
Read more
2019 World Pharma Pricing and Market Access congress
Posted on March 14, 20192019 World Pharma Pricing and Market Access congress Maverex are excited to announce that we will be attending the 2019 World Pharma Pricing and Market Access congress next week. Held at the Beurs van Berlage Conference Centre, Amsterdam, PPMA is Europe’s leading pricing, access and evidence congress. Our team will be available throughout the …
Read more
Introducing Maverex eGVDs
Posted on February 13, 2019Introducing Maverex eGVDs We’re really excited to introduce the latest version of our eGVD platform, featuring innovative new features and a clean and modern design that’s really easy to use. At Maverex we have always believed that electronic GVDs are the future for providing a central resource for value communications with payers and other …
Read more
A busy start to 2019
Posted on January 18, 2019A busy start to 2019 The first few weeks of 2019 have flown by here at Maverex, and with February fast approaching we’d like to share some of the things we’re looking forward to in the coming months: New and improved eGVD products We’re continually tweaking our eGVD and Value Story online and app-based …
Read more
New Maverex products at ISPOR Barcelona
Posted on October 29, 2018Our innovative new products at ISPOR Barcelona Several of the Maverex team will be flying to Barcelona for ISPOR Europe very soon for all the latest in Health Economics and Outcomes research, to catch up with our industry friends and clients, and of course indulge in some of Barcelona’s fantastic food and culture. This …
Read more
Maverex research presentations at ISPOR Barcelona 2018
Posted on September 24, 2018Maverex research presentations at ISPOR Barcelona 2018 We’re happy to announce that there will be several Maverex poster presentations at ISPOR Europe 2018, covering various research topics that we’ve been busy working on over the last few months. The first is a review of the most common mistakes made in the reporting of indirect …
Read more